Critical Outcome Technologies Announces Warrant Expiry Date Amendment

Critical Outcome Technologies Inc. (COTI) (TSX VENTURE:COT) announced today that
it is extending the expiry date of 12,500,000 common share purchase warrants
(Warrants) issued as part of three tranches of a non-brokered private placement
on March 25, April 7 and April 21, 2011 respectively. Each Warrant entitled its
holder to purchase one common share of the Company at an exercise price of $0.30
per share for a period of 18 months from the date of issue. 


Effective September 6, 2012, the Company amended the terms of the Warrants to
extend the expiry date of all the Warrants to 5:00 p.m. EDT on October 31, 2013
(the "Expiry Date"). The Expiry Date is now being further amended to extend the
expiry date to 5:00 p.m. EDT on May 31, 2014 (the "New Expiry Date"). 


The New Expiry Date of the Warrants will be reduced to a period of 21 days if,
for any ten consecutive trading days during the unexpired term of the Warrant
(the "Premium Trading Days"), the closing price of the Common Shares on the TSX
Venture Exchange equals or exceeds $0.37. If this occurs, the reduced exercise
period of 21 days will begin seven calendar days after the tenth Premium Trading
Day. 


The remaining terms and conditions of the Warrants remain unchanged. The Company
will deliver a Notice of Amendment reflecting the amended expiry date to the
registered holders of the Warrants.


About Critical Outcome Technologies Inc. (COTI) 

COTI is a leading-edge technology company specializing in accelerating the
discovery and development of small molecules - dramatically reducing the time
and cost to bring new drugs to market. COTI'S proprietary artificial
intelligence system, CHEMSAS(R), utilizes a series of predictive computer models
to identify compounds with a high probability of being successfully developed
from disease specific drug discovery through chemical optimization and
preclinical testing. These compounds are targeted for a variety of diseases,
particularly those for which current treatments are either lacking or
ineffective.


Follow @CriticalOutcome on Twitter at http://twitter.com/CriticalOutcome 

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term
is defined in policies of the TSX Venture Exchange) accepts responsibility for
the adequacy or accuracy of this release.


FOR FURTHER INFORMATION PLEASE CONTACT: 
Critical Outcome Technologies Inc.
Dr. Wayne Danter
President & CEO
519-858-5157
wdanter@criticaloutcome.com
www.criticaloutcome.com


Heisler Communications
Trevor Heisler
Investor Relations
416-500-8061
trevor@heislercommunications.com

Cotinga Pharmaceuticals (TSXV:COT)
Graphique Historique de l'Action
De Nov 2024 à Déc 2024